Key Highlights

  • Adherium shares touched a 52-week low during the session on Monday 9 November 2026 and closed at $0.052, down 14.75%.
  • Remote patient monitoring subscription accrual Revenue was $539k in the quarter, up 12.5% on Q4 FY26.
  • Cumulative device shipments reached 6,392 and device activations reached 4,732.

Adherium Ltd (ASX:ADR) touched a 52-week low during the Trading session on Monday, 9 November 2026, and closed at $0.052, down 14.75%. Adherium is a digital respiratory management company that develops the FDA-cleared Hailie Sensor and Smartinhaler platform.

Latest Development: Quarterly Report, 30 October 2026

Adherium released its quarterly activities report on 30 October 2026. Remote patient monitoring subscription accrual revenue was $539k, up 12.5% from A$479k in Q4 FY26. The company described this as the fifth consecutive quarter of record RPM revenue.

Customer cash receipts were $544k, up 33% on the prior quarter, including a $257,917 study receipt from AstraZeneca received on 9 October 2026. The company added 1,033 device shipments and 900 activations in the quarter.

Leadership and Partnerships

John Perry was appointed Interim Chief Executive Officer, as announced on 29 July 2026. After quarter end, the company partnered with Florida Lung, Asthma & Sleep Specialists to extend the Hailie platform into Central Florida.

About the Company

Adherium supplies digital respiratory products and recurring monitoring services, with revenue tied to patient activations and subscriptions. It operates in Australia and the United States.

Sector Context

Digital health businesses are often judged on Recurring Revenue growth, reimbursement pathways and the speed of clinical adoption, which can take longer than expected.

Risks and What to Watch Ahead

Revenue remains modest in absolute terms, and the company is in a Leadership transition. Reimbursement and adoption rates are key uncertainties.

Watch items include the next quarterly report, activation trends and any permanent chief executive appointment.

Final Word

Adherium's Quarterly Report shows recurring revenue and device numbers rising over the quarter, alongside a new interim chief executive and a US partnership. The report covers the quarter to 30 September 2026.